The role of mir-16 in modulating the drug resistance was widely investigated in relation to BCL2 targeting [43,44,45,46], but there is no evidence about a possible role of this miRNA in affecting the primary resistance to TKIs in NSCLC. This evidence concerns the gene BCL2 and non-small cell lung carcinoma.